Company News: Curetis to Hold Investor Conference Call with Webcast on U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge
After having obtained the De Novo clearance by the U.S. FDA for its Unyvero System and the Unyvero LRT Application Cartridge, Curetis N.V. will host a public investor conference call with webcast today, April 4, 2018, at 03:00 pm CEST / 09:00 am EDT.
In this call Curetis will provide an overview on the Unyvero System and LRT Cartridge for the U.S. market, the FDA De Novo clearance decision and the underlying U.S. clinical evaluation data, and the planned U.S. launch and market development activities.
The conference call will be supplemented by a presentation, which can be accessed during the call at http://www.curetis.com/en/investors/background-information.html (participants’ passcode curetis0418).
A slide presentation accompanying the investor update conference call will be accessible at http://www.audio-webcast.com/ using the passcode curetis0418.
To access the call, please dial the following numbers using the passcode 93120684#
BEL: +32 11500307
D: +49 69 222229043
NL: +31 1071 372 73
UK: +44 20 30092452
US: +1 855 4027766
For further international dial-in numbers, please open the following link:
The recorded webcast will be available after completion of the conference call at: